B-Cell CD20 Expression
Used primarily to monitor response to rituximab therapy.
New York DOH Approval Status
Green (sodium heparin). Also acceptable: Lavender (EDTA) or pink (K2EDTA).
Transport 5 mL whole blood.
Room temperature. Also acceptable: Refrigerated. Specimen should be received within 48 hours of collection for optimal viable testing.
Frozen specimens. Specimens greater than 48 hours old. Clotted or hemolyzed specimens.
Provide CBC, Wright's stained smear (if available), clinical history, differential diagnosis, and any relevant pathology reports.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Analyte Specific Reagent (ASR)
Monoclonal antibody-based therapies such as Rituximab that target the CD20 antigen, are being used to treat patients with a variety of B-cell lymphomas and leukemias, as well as in the treatment of some autoimmune disorders. The effectiveness of these therapies for B-cell lymphomas and leukemias requires that the B-cell leukemia or lymphoma cells express CD20. This test examines whether surface CD20 antigen expression can be identified on any B-cells present in the submitted specimen. This test will also identify CD19 antigen expression and the percentage of expression.
|Component Test Code*
|Component Chart Name
- CD20 on B Cells
- Rituximab Therapy CD20